First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC
T3011（一种表达IL-12和PD-1的溶瘤性HSV抗体）的首次人体I/IIa期研究，通过瘤内注射（IT）给药，作为单药疗法治疗晚期实体瘤，包括复发性或转移性头颈部鳞状细胞癌（HNSCC）。
期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-026-04695-1
Ji, Dongmei; Fu, Wenmin; Liu, Yonghong; Shen, Weina; Kuang, Muyu; Ning, Zhouyu; Sang, Youzhou; Chen, Guangliang; Zhang, Jian; Zhou, Zijie; Xu, Dashuang; Jin, Xu; Wu, Junlong; Zhou, Xusha; Zhao, Jing; Wang, Lei; Liu, Yukun; Zhang, Xi; Yan, Runbin; Chen, Xiaoqing; Zhou, Grace; Niu, Jiaxin; Hu, Xichun
